KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Chemed (CHE) Cost of Revenue (2016 - 2025)

Chemed (CHE) has 17 years of Cost of Revenue data on record, last reported at $414.2 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 2.04% year-over-year to $414.2 million; the TTM value through Dec 2025 reached $1.7 billion, up 8.23%, while the annual FY2025 figure was $1.7 billion, 8.23% up from the prior year.
  • Cost of Revenue reached $414.2 million in Q4 2025 per CHE's latest filing, down from $428.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $434.1 million in Q2 2025 and bottomed at $336.3 million in Q4 2021.
  • Average Cost of Revenue over 5 years is $374.4 million, with a median of $366.5 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: fell 3.9% in 2022, then increased 13.26% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $336.3 million in 2021, then rose by 3.94% to $349.6 million in 2022, then grew by 2.51% to $358.3 million in 2023, then rose by 13.26% to $405.9 million in 2024, then increased by 2.04% to $414.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $414.2 million in Q4 2025, $428.0 million in Q3 2025, and $434.1 million in Q2 2025.